Marrone Bio Innovations Regains Compliance with Nasdaq Minimum Bid Price Requirement
DAVIS, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today announced that it received notice from The Nasdaq Stock Market, LLC ("Nasdaq") on June 19, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
“We are pleased to announce to our shareholders that the Company has regained full compliance with Nasdaq’s continued listing requirements,” said Pam Marrone, Founder and Chief Executive Officer of Marrone Bio Innovations. “With this matter now resolved, our officers and directors will continue to remain focused on driving growth and creating sustainable shareholder value over the long term.”
About Marrone Bio Innovations
Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Facebook, Twitter, LinkedIn and Instagram.
Marrone Bio Innovations Contact: